Evidence map›Paper›PMID 36522735›Full record

SynthesisRespiratory research2022

Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis.

Marc Miravitlles, Juan Luís García-Rivero, Xavier Ribera, Jordi Galera, Alejandra García, Rosa Palomino, Xavier Pomares

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Stepwise management of COPD: What is next after bronchodilation?Therapeutic advances in respiratory disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Marc MiravitllesPneumology Department, Hospital Universitari Vall d'HebronVall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. marcm@separ.es.
Juan Luís García-RiveroPneumology Department, President of ACINAR, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Xavier RiberaBoehringer Ingelheim España S.A., Barcelona, Spain.
Jordi GaleraTFS Health Science, Barcelona, Spain.
Alejandra GarcíaMarket Access AreaPharmalex Spain, Barcelona, Spain.
Rosa PalominoMarket Access AreaPharmalex Spain, Barcelona, Spain.
Xavier PomaresPneumology Department, Hospital de Sabadell, Hospital Universitari Parc TaulíInstitut Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.
Boehringer Ingelheim (Spain) · ESMarqués de Valdecilla University Hospital · ESTeulades i Façanes Multifuncionals (Spain) · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Institut de Recerca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPersistent airflow limitation and dyspnoea may reduce chronic obstructive pulmonary disease (COPD) patients exercise capacity and physical activity, undermining their physical status and quality of life. Long-acting muscarinic antagonists and long-acting beta-2 agonists (LAMA/LABA) combinations are amongst moderate-to-severe COPD recommended treatments. This article analyses LAMA/LABA combinations effect on COPD patients exercise capacity and physical activity outcomes.

methodsA systematic review and meta-analysis of double-blind randomized controlled trials comparing LAMA/LABA combinations against monotherapy or placebo was conducted.

resultsSeventeen articles were identified (N = 4041 patients). In endurance shuttle walk test and constant work rate cycle ergometry, LAMA/LABA combinations obtained better results than placebo, but not monotherapy, whereas in 6-min walking test, results favoured LAMA/LABA over monotherapy (four studies), but not over placebo (one study). Moreover, LAMA/LABA combinations obtained better results than placebo in number of steps per day, reduction in percentage of inactive patients and daily activity-related energy expenditure, and better than monotherapy when measuring time spent on ≥ 1.0-1.5, ≥ 2.0 and ≥ 3.0 metabolic equivalents of task activities.

conclusionsLAMA/LABA combinations in COPD patients provided better results than monotherapy or placebo in most exercise capacity and physical activity outcomes.

Indexed as

Adrenergic beta-2 Receptor AgonistsPulmonary Disease, Chronic ObstructiveAdministration, InhalationBronchodilator AgentsDrug CombinationsDrug Therapy, CombinationExerciseExercise ToleranceHumansMuscarinic AntagonistsQuality of LifeRandomized Controlled Trials as TopicAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsMuscarinic AntagonistsBronchodilatorsCOPDExercise capacityLABALAMAPhysical activity

Identifiers

PMID36522735
PMCPMC9753337
OpenAlexW4311504721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.